Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04922281 · ClinicalTrials.gov registry record · NA
Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation
A NA study of Cardiovascular Diseases and Atrial Fibrillation, sponsored by University of Rochester.
- Active
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT04922281: Active NA study of Cardiovascular Diseases and Atrial Fibrillation, sponsored by University of Rochester.
NCT04922281 is a NA study of Cardiovascular Diseases and Atrial Fibrillation that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 120 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04922281, a NA study of Cardiovascular Diseases and Atrial Fibrillation, is active but no longer recruiting, sponsored by University of Rochester.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
To prospectively investigate the efficacy of an insertable cardiac monitor-guided atrial fibrillation (AF) management in reducing subsequent AF burden in patients with persistent or paroxysmal AF undergoing atrial catheter ablation (CA).
Primary Outcome
The primary endpoint of the trial is total AF burden between 3 and 15 months after the index CA procedure (i.e. over 1-year post-blanking), as detected by an ICM which will be inserted prior to or at the time of the CA procedure, existing CIED, or non-invasive LT-ECG monitor in all study subjects. AF recurrence is defined as any episode of AF lasting \>30 seconds. AF burden will be defined as the mean amount of time spent in AF over the pre-specified period of time (excluding short AF episodes o
Conditions Studied
Interventions
- DEVICE Insertable Cardiac Monitor or external non-invasive LT-ECG patch
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-02-28 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT04922281 still lists
NCT04922281 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).
The record links to 5 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Insertable Cardiac Monitor or external non-invasive LT-ECG patch is the first listed.
NCT04922281 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04922281 about?
NCT04922281 is a clinical study titled "Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation". To prospectively investigate the efficacy of an insertable cardiac monitor-guided atrial fibrillation (AF) management in reducing subsequent AF burden in patients with persistent or paroxysmal AF undergoing atrial catheter ablation (CA).
What is the current status of trial NCT04922281?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2022-02-28. Estimated completion is 2026-12-31.
What conditions does trial NCT04922281 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Atrial Fibrillation, Heart Diseases, Arrhythmias, Cardiac, Pathologic Processes.
What interventions are being tested in trial NCT04922281?
The interventions under investigation include: Insertable Cardiac Monitor or external non-invasive LT-ECG patch (DEVICE).
Who is sponsoring clinical trial NCT04922281?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04922281 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04922281's enrollment target sits among peer trials
120 181st of 300 higher than 116 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI